<DOC>
	<DOCNO>NCT02145715</DOCNO>
	<brief_summary>Velcade ( bortezomib ) , thalidomide dexamethasone ( VTD ) demonstrate highly effective combination patient previously untreated relapsed multiple myeloma . In previously untreated patient VTD demonstrate clear superiority TD induction therapy prior plan tandem autologous stem cell transplant . The rationale trial combine 'gold standard ' antiMM combination HDAC inhibitor Panobinostat . There emerge data support concept clinical synergy BTZ HDACi 's . The purpose study determine maximum tolerate dose ( MTD ) estimate response rate panobinostat , administer combination VTD , subject relapse relapsed/refractory multiple myeloma .</brief_summary>
	<brief_title>Velcade , Thalidomide , Dexamethasone Panobinostat Treatment Panobinostat Maintenance Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients previous diagnosis multiple myeloma base IMWG 2003 definition : Monoclonal immunoglobulin ( M component ) electrophoresis , immunofixation serum total 24 hour urine Bone marrow ( clonal ) plasma cell ≥ 10 % biopsy proven plasmacytoma Related organ tissue impairment ( CRAB symptom , anemia , hypercalcemia , lytic bone lesion , renal insufficiency , hyperviscosity , amyloidosis recurrent infection ) Relapsed relapsedandrefractory myeloma receive 14 prior line require treatment Able give inform consent willing follow study protocol Aged 18 year ECOG Performance Status ≤2 Required laboratory value within 14 day registration : Absolute neutrophil count ≥1.0 x 109/L . Platelet count ≥100 x 109/L . Haemoglobin ≥8.0g/dL . Bilirubin ≤2 upper limit normal ( ULN ) AST and/or ALT ≤2.5 ULN ; except subject know hepatic involvement , AST and/or ALT ≤5.0 ULN Serum creatinine ≤2.0 ULN Corrected calcium ≤2.8 mmol/L . Anticipated survival least 3 month Evaluable disease per modify IWG criterion , utilise follow assessment appropriate : Serum M protein ≥ 10g/l . Urine M protein ≥ 200mg/24 hour Serum free light chain assay : involve FLC level ≥ 100mg/l . Provided serum FLC ratio abnormal Female subject childbearing potential must negative pregnancy test baseline agree use dual method contraception duration study must continue 3 month end treatment . Male subject must agree use barrier method contraception duration study sexually active female childbearing potential must continue 3 month end treatment . Pregnant ( positive pregnancy test ) breastfeed woman . Nonsecretory Multiple Myeloma Previous antitumour therapy , include prior experimental agent approve antitumour small molecule biologics , within 28 day start protocol treatment . Steroid therapy permit ( maximum 160 mg dexamethasone equivalent ) , must stop 48 hour prior study drug administration . Bisphosphonates bone disease radiotherapy palliative intent also permit . Concurrent previous malignancy ( &lt; 12 month post end treatment ) sit exception appropriately treat localised epithelial skin cervical cancer , incidental histologic finding prostate cancer ( TMN stage T1a 1b ) . Patients history ( ≥12 month ) tumours may enter . Poorly control serious medical psychiatric illness , Investigator 's opinion , likely interfere participation and/or compliance clinical study Patients significant cardiovascular disease ( e.g . history congestive heart failure require therapy , presence severe valvular heart disease , presence atrial ventricular arrhythmia require treatment , uncontrolled hypertension , history clinically significant QTc abnormality ) Active symptomatic fungal , bacterial , and/or viral infection include know active HIV know viral ( A , B , C ) hepatitis . Gastrointestinal disorder may interfere absorption study drug Patients refractory prior bortezomib , i.e . achieve least MR , progress therapy within 60 day last dose Participants peripheral neuropathy CTC grade 2 high grade 1 pain within 14 day prior registration Any history know hypersensitivity study medication excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>